Moleculin Biotech Q2 EPS $(1.70) Beats $(2.31) Estimate
Portfolio Pulse from Benzinga Newsdesk
Moleculin Biotech (NASDAQ:MBRX) reported a Q2 EPS of $(1.70), beating the analyst consensus estimate of $(2.31) by 26.41%. This represents a 43.71% improvement over the same period last year.
August 14, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moleculin Biotech reported a Q2 EPS of $(1.70), beating the analyst consensus estimate of $(2.31) by 26.41%. This is a significant improvement over the same period last year, where the EPS was $(3.02).
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact MBRX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100